Quidel Gets De Novo FDA Clearance for Combined HSV, VZV Assay | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said today after the close of the market that it has received de novo clearance from the US Food and Drug Administration to market its Lyra Direct HSV 1+2/VZV multiplex real-time assay.

Quidel's assay detects and differentiates herpes simplex viruses 1 and 2 and varicella-zoster virus nucleic acids isolated and purified from swab specimens taken from cutaneous or mucocutaneous lesions on symptomatic patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.